| pubmed-article:16718274 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16718274 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:16718274 | lifeskim:mentions | umls-concept:C0151779 | lld:lifeskim |
| pubmed-article:16718274 | lifeskim:mentions | umls-concept:C0027627 | lld:lifeskim |
| pubmed-article:16718274 | lifeskim:mentions | umls-concept:C1257954 | lld:lifeskim |
| pubmed-article:16718274 | lifeskim:mentions | umls-concept:C0684321 | lld:lifeskim |
| pubmed-article:16718274 | lifeskim:mentions | umls-concept:C0439064 | lld:lifeskim |
| pubmed-article:16718274 | lifeskim:mentions | umls-concept:C0205197 | lld:lifeskim |
| pubmed-article:16718274 | lifeskim:mentions | umls-concept:C0205221 | lld:lifeskim |
| pubmed-article:16718274 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:16718274 | pubmed:dateCreated | 2006-5-23 | lld:pubmed |
| pubmed-article:16718274 | pubmed:abstractText | Experimental and clinical evidence indicates that non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors may have anti-cancer activities. Here we report on a patient with a metastatic melanoma of the leg who experienced a complete and sustained regression of skin metastases upon continuous single treatment with the cyclooxygenase-2 inhibitor rofecoxib. Our observations indicate that the inhibition of cyclooxygenase-2 can lead to the regression of disseminated skin melanoma metastases, even after failure of chemotherapy. | lld:pubmed |
| pubmed-article:16718274 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16718274 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16718274 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16718274 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16718274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16718274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16718274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16718274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16718274 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16718274 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:16718274 | pubmed:issn | 0960-8931 | lld:pubmed |
| pubmed-article:16718274 | pubmed:author | pubmed-author:LejeuneFerdy... | lld:pubmed |
| pubmed-article:16718274 | pubmed:author | pubmed-author:RüeggCurzioC | lld:pubmed |
| pubmed-article:16718274 | pubmed:author | pubmed-author:MonnierYanY | lld:pubmed |
| pubmed-article:16718274 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16718274 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:16718274 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16718274 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16718274 | pubmed:pagination | 263-5 | lld:pubmed |
| pubmed-article:16718274 | pubmed:dateRevised | 2007-3-7 | lld:pubmed |
| pubmed-article:16718274 | pubmed:meshHeading | pubmed-meshheading:16718274... | lld:pubmed |
| pubmed-article:16718274 | pubmed:meshHeading | pubmed-meshheading:16718274... | lld:pubmed |
| pubmed-article:16718274 | pubmed:meshHeading | pubmed-meshheading:16718274... | lld:pubmed |
| pubmed-article:16718274 | pubmed:meshHeading | pubmed-meshheading:16718274... | lld:pubmed |
| pubmed-article:16718274 | pubmed:meshHeading | pubmed-meshheading:16718274... | lld:pubmed |
| pubmed-article:16718274 | pubmed:meshHeading | pubmed-meshheading:16718274... | lld:pubmed |
| pubmed-article:16718274 | pubmed:meshHeading | pubmed-meshheading:16718274... | lld:pubmed |
| pubmed-article:16718274 | pubmed:meshHeading | pubmed-meshheading:16718274... | lld:pubmed |
| pubmed-article:16718274 | pubmed:meshHeading | pubmed-meshheading:16718274... | lld:pubmed |
| pubmed-article:16718274 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16718274 | pubmed:articleTitle | Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. | lld:pubmed |
| pubmed-article:16718274 | pubmed:affiliation | Department of Visceral Surgery, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne Switzerland. Ferdy.Lejeune@chuv.ch | lld:pubmed |
| pubmed-article:16718274 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16718274 | pubmed:publicationType | Case Reports | lld:pubmed |
| entrez-gene:5743 | entrezgene:pubmed | pubmed-article:16718274 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:16718274 | lld:entrezgene |
| lhgdn:association:30196 | lhgdn:found_in | pubmed-article:16718274 | lld:lhgdn |
| lhgdn:association:30310 | lhgdn:found_in | pubmed-article:16718274 | lld:lhgdn |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16718274 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16718274 | lld:pubmed |
